Tango Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Tango Therapeutics, Inc. (TNGX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 8.40 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-11
- Tango Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 1.39M shares, a 267.71% increase year-over-year.
- Tango Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 7.01M shares, a 56.90% increase year-over-year.
- Tango Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 263.69K shares, a 36.68% decline year-over-year.
- Tango Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 167.26K shares, a 55.72% decline year-over-year.
- Tango Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 5.28M shares, a 5.34% decline from fiscal 2024.
- Tango Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 5.58M shares, a 2.72% increase from fiscal 2023.
- Tango Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 5.43M shares, a 7.16% increase from fiscal 2022.
- Tango Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 5.07M shares, a 18.32% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.39M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | 8.40M shares 10-Q · filed 2026-08-11 | 8.67M shares derived: sum of 3 quarters · filed 2026-08-11 | 8.83M shares derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 7.01M shares 10-Q · filed 2026-05-13 | 7.27M shares derived: sum of 2 quarters · filed 2026-05-13 | 7.44M shares derived: sum of 3 quarters · filed 2026-05-13 | 7.82M shares derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | 263.69K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 430.95K shares derived: sum of 2 quarters · filed 2026-03-05 | 810.20K shares derived: sum of 3 quarters · filed 2026-03-05 | 5.28M shares 10-K · filed 2026-03-05 |
| 2025-09-30 | 167.26K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | 546.51K shares derived: sum of 2 quarters · filed 2025-11-04 | 5.01M shares 10-Q · filed 2025-11-04 | 5.43M shares derived: sum of 4 quarters · filed 2025-11-04 |
| 2025-06-30 | 379.25K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 4.85M shares 10-Q · filed 2025-08-05 | 5.26M shares derived: sum of 3 quarters · filed 2025-08-05 | 5.64M shares derived: sum of 4 quarters · filed 2025-08-05 |
| 2025-03-31 | 4.47M shares 10-Q · filed 2025-05-12 | 4.88M shares derived: sum of 2 quarters · filed 2025-05-12 | 5.26M shares derived: sum of 3 quarters · filed 2025-05-12 | 5.75M shares derived: sum of 4 quarters · filed 2025-05-12 |
| 2024-12-31 | 416.45K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 794.19K shares derived: sum of 2 quarters · filed 2025-02-27 | 1.29M shares derived: sum of 3 quarters · filed 2025-02-27 | 5.58M shares 10-K · filed 2025-02-27 |
| 2024-09-30 | 377.74K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 870.32K shares derived: sum of 2 quarters · filed 2024-11-06 | 5.16M shares 10-Q · filed 2024-11-06 | 5.47M shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 492.58K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | 4.78M shares 10-Q · filed 2024-08-07 | 5.10M shares derived: sum of 3 quarters · filed 2024-08-07 | 5.51M shares derived: sum of 4 quarters · filed 2024-08-07 |
| 2024-03-31 | 4.29M shares 10-Q · filed 2024-05-08 | 4.60M shares derived: sum of 2 quarters · filed 2024-05-08 | 5.02M shares derived: sum of 3 quarters · filed 2024-05-08 | 5.46M shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | 314.20K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | 726.65K shares derived: sum of 2 quarters · filed 2024-03-18 | 1.17M shares derived: sum of 3 quarters · filed 2024-03-18 | 5.43M shares 10-K · filed 2024-03-18 |
| 2023-09-30 | 412.45K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | 855.40K shares derived: sum of 2 quarters · filed 2023-11-08 | 5.11M shares 10-Q · filed 2023-11-08 | 5.67M shares derived: sum of 4 quarters · filed 2023-11-08 |
| 2023-06-30 | 442.95K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | 4.70M shares 10-Q · filed 2023-08-07 | 5.25M shares derived: sum of 3 quarters · filed 2023-08-07 | 5.63M shares derived: sum of 4 quarters · filed 2023-08-07 |
| 2023-03-31 | 4.26M shares 10-Q · filed 2023-05-09 | 4.81M shares derived: sum of 2 quarters · filed 2023-05-09 | 5.19M shares derived: sum of 3 quarters · filed 2023-05-09 | 5.82M shares derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | 552.30K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | 932.92K shares derived: sum of 2 quarters · filed 2023-03-27 | 1.57M shares derived: sum of 3 quarters · filed 2023-03-27 | 5.07M shares 10-K · filed 2023-03-27 |
| 2022-09-30 | 380.63K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 1.01M shares derived: sum of 2 quarters · filed 2022-11-10 | 4.51M shares 10-Q · filed 2022-11-10 | 5.15M shares derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | 632.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | 4.13M shares 10-Q · filed 2022-08-10 | 4.77M shares derived: sum of 3 quarters · filed 2022-08-10 | |
| 2022-03-31 | 3.50M shares 10-Q · filed 2022-05-11 | 4.14M shares derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2021-12-31 | 636.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | 6.20M shares 10-K · filed 2022-03-28 | ||
| 2021-09-30 | 5.56M shares 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |